289 related articles for article (PubMed ID: 30781783)
1. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
[TBL] [Abstract][Full Text] [Related]
3. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells.
Ahmad A; Sarkar SH; Bitar B; Ali S; Aboukameel A; Sethi S; Li Y; Bao B; Kong D; Banerjee S; Padhye SB; Sarkar FH
Mol Cancer Ther; 2012 Oct; 11(10):2193-201. PubMed ID: 22821148
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
5. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
6. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
7. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
8. MiR-145 and miR-203 represses TGF-β-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
Hu H; Xu Z; Li C; Xu C; Lei Z; Zhang HT; Zhao J
Lung Cancer; 2016 Jul; 97():87-94. PubMed ID: 27237033
[TBL] [Abstract][Full Text] [Related]
9. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Gohlke L; Alahdab A; Oberhofer A; Worf K; Holdenrieder S; Michaelis M; Cinatl J; Ritter CA
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834189
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer.
Li C; Wan L; Liu Z; Xu G; Wang S; Su Z; Zhang Y; Zhang C; Liu X; Lei Z; Zhang HT
Cancer Lett; 2018 Apr; 418():185-195. PubMed ID: 29339211
[TBL] [Abstract][Full Text] [Related]
11. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
12. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
13. miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells.
Li J; Wang Y; Luo J; Fu Z; Ying J; Yu Y; Yu W
FEBS Lett; 2012 Oct; 586(20):3761-5. PubMed ID: 23010597
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
[TBL] [Abstract][Full Text] [Related]
15. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
16. Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis.
Zhang N; Liu Y; Wang Y; Zhao M; Tu L; Luo F
Drug Des Devel Ther; 2017; 11():969-983. PubMed ID: 28405157
[TBL] [Abstract][Full Text] [Related]
17. Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.
Wang J; Chen Y; Xiang F; Li M; Li H; Chi J; Ren K
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1505-1512. PubMed ID: 28918673
[TBL] [Abstract][Full Text] [Related]
18. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
20. A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC.
Krentz Gober M; Collard JP; Thompson K; Black EP
Sci Rep; 2017 Jun; 7(1):4202. PubMed ID: 28646226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
